Compare AGEN & PMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGEN | PMM |
|---|---|---|
| Founded | 1994 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.8M | 269.4M |
| IPO Year | 1999 | 1994 |
| Metric | AGEN | PMM |
|---|---|---|
| Price | $7.70 | $6.22 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 94.5K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.68% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $42,877,086.00 | N/A |
| Revenue This Year | $107.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $8.14 | $27.43 |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $2.71 | $5.80 |
| 52 Week High | $8.85 | $6.60 |
| Indicator | AGEN | PMM |
|---|---|---|
| Relative Strength Index (RSI) | 57.42 | 44.35 |
| Support Level | $2.97 | $6.07 |
| Resistance Level | $8.76 | $6.35 |
| Average True Range (ATR) | 0.58 | 0.06 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 60.69 | 32.11 |
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.